Cited by 41Thyroid Disorders and TreatmentsThyroid and Parathyroid SurgeryThyroid Cancer Diagnosis and Treatment

Novel thyroxine formulations: a further step toward precision medicine

Virili, Camilla, Trimboli, Pierpaolo, Centanni, Marco·2019·Endocrine

Abstract

Levothyroxine (T4) is a critical-dose drug, because little variations in the blood concentration may cause treatment failure as well as iatrogenic thyrotoxicosis. Despite the dose response of this drug being more carefully titrated nowadays, several papers still report that a significant fraction of patients treated with levothyroxine demonstrate a TSH which is not on target. Moreover, some widespread gastrointestinal disorders as well as interfering drugs and foods may cause the "refractoriness" of a significant number of patients to an expected dose of thyroxine. The increasing awareness of the mechanisms interfering with the oral thyroid hormone bioavailability and the body of evidence regarding the complexity of treatment in certain classes of patients prompted pharmaceutical research to identify new hormonal formulations to optimize the performance of this drug. In this brief review, the progression of the scientific knowledge of novel T4 formulations use has been analyzed.

Integrity signals

Registry

Crossref · 10.1007/s12020-019-02049-x

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Non-tablet LT4 formulations (liquid solution and softgel capsule) have been manufactured and commercialized for clinical practice to overcome gastrointestinal absorption issues, although they are not available in every country.

    “In an attempt to overcome the above-mentioned issues with gastrointestinal absorption (such as intake interference, drug interference, and pH dependence), non-tablet LT4 formulations, i.e., liquid solution (LS) and softgel capsule (SG), have been manufactured and commercialized for clinical practice, although they are not available in every country (13, 107).”
  • LS of LT4 is prepared with glycerol (and ethanol at the beginning of its commercialization), while SG represents a gelled form of LS and contains LT4 dissolved in water and glycerin.

    “On the other hand, LS of LT4 is prepared with glycerol (and ethanol at the beginning of its commercialization), while SG represents a gelled form of LS and contains LT4 dissolved in water and glycerin (107).”
  • LT4 salt rapidly replaced DTE and became the standard therapy for hypothyroidism because it had fewer adverse effects and more accurate dosing.

    “LT4 salt rapidly replaced DTE and became the standard therapy for hypothyroidism as there were fewer adverse effects and more accurate dosing (141).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Virili, C., Trimboli, P., & Centanni, M.
Affiliations
  • Sapienza University of Rome (IT)
  • Ente Ospedaliero Cantonale (CH)
Corresponding author
Centanni, Marco
Venue
Endocrine
Published
2019-10
Volume
66
Issue
1
Pages
87-94
ISSN
  • 0969-711X (ISSN-L)
  • 1355-008X
  • 1559-0100
OpenAlex
W2980531828
Cited by
41
References
78
Citations by year
2026: 4 · 2025: 6 · 2024: 4 · 2023: 2 · 2022: 9 · 2021: 8 · 2020: 6 · 2019: 1
FWCI
0.92
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
levothyroxine, precision medicine, drug interactions, gastrointestinal diseases, thyroid-stimulating hormone, thyrotoxicosis, dose titration
MeSH terms
Dosage Forms, Humans, Thyroxine, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review